These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 12091605)

  • 1. Anaemia, rHuEPO resistance, and cardiovascular disease in end-stage renal failure; links to inflammation and oxidative stress.
    Stenvinkel P; Bárány P
    Nephrol Dial Transplant; 2002; 17 Suppl 5():32-7. PubMed ID: 12091605
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anaemia and inflammation: what are the implications for the nephrologist?
    Stenvinkel P
    Nephrol Dial Transplant; 2003 Nov; 18 Suppl 8():viii17-22. PubMed ID: 14607995
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Non-erythropoietin-based anaemia management in chronic kidney disease.
    Hörl WH
    Nephrol Dial Transplant; 2002; 17 Suppl 11():35-8. PubMed ID: 12386256
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adjunctive therapy in anaemia management.
    Hörl WH
    Nephrol Dial Transplant; 2002; 17 Suppl 5():56-9. PubMed ID: 12091609
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nonalcoholic fatty liver disease (NAFLD)--is it a new marker of hyporesponsiveness to recombinant human erythropoietin in patients that are on chronic hemodialysis?
    Orlic L; Mikolasevic I; Lukenda V; Racki S; Stimac D; Milic S
    Med Hypotheses; 2014 Dec; 83(6):798-801. PubMed ID: 25456789
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Is it time for a paradigm shift? Is erythropoietin deficiency still the main cause of renal anaemia?
    Eschbach JW; Varma A; Stivelman JC
    Nephrol Dial Transplant; 2002; 17 Suppl 5():2-7. PubMed ID: 12091599
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Erythropoietin resistance: the role of inflammation and pro-inflammatory cytokines.
    Macdougall IC; Cooper AC
    Nephrol Dial Transplant; 2002; 17 Suppl 11():39-43. PubMed ID: 12386257
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Melatonin prevents oxidative stress resulting from iron and erythropoietin administration.
    Herrera J; Nava M; Romero F; Rodríguez-Iturbe B
    Am J Kidney Dis; 2001 Apr; 37(4):750-7. PubMed ID: 11273875
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Does long-term treatment of renal anaemia with recombinant erythropoietin influence oxidative stress in haemodialysed patients?
    Sommerburg O; Grune T; Hampl H; Riedel E; van Kuijk FJ; Ehrich JH; Siems WG
    Nephrol Dial Transplant; 1998 Oct; 13(10):2583-7. PubMed ID: 9794564
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Variations in erythropoiesis and serum ferritin during erythropoietin therapy for anaemia of end-stage renal disease.
    Barosi G; Merlo C; Palestra P; Liberato NL; Guarnone R; Di Dio F; Piazza V; Salvadeo A
    Acta Haematol; 1993; 90(1):13-8. PubMed ID: 8237268
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of inflammation in the anaemia of end-stage renal disease.
    Stenvinkel P
    Nephrol Dial Transplant; 2001; 16 Suppl 7():36-40. PubMed ID: 11590255
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Erythropoietin hyporesponsiveness: from iron deficiency to iron overload.
    Tarng DC; Huang TP; Chen TW; Yang WC
    Kidney Int Suppl; 1999 Mar; 69():S107-18. PubMed ID: 10084294
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anaemia of critical illness-- implications for understanding and treating rHuEPO resistance.
    Eckardt KU
    Nephrol Dial Transplant; 2002; 17 Suppl 5():48-55. PubMed ID: 12091608
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Renal disease. II. The clinical impact of recombinant human erythropoietin.
    Muirhead N
    J R Coll Physicians Lond; 1997; 31(2):125-30. PubMed ID: 9131506
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oxidative stress in end-stage renal disease: an emerging threat to patient outcome.
    Locatelli F; Canaud B; Eckardt KU; Stenvinkel P; Wanner C; Zoccali C
    Nephrol Dial Transplant; 2003 Jul; 18(7):1272-80. PubMed ID: 12808161
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Renal risk-benefit determinants of recombinant human erythropoietin therapy in the remnant kidney rat model - hypertension, anaemia, inflammation and drug dose.
    Ribeiro S; Garrido P; Fernandes J; Vala H; Rocha-Pereira P; Costa E; Belo L; Reis F; Santos-Silva A
    Clin Exp Pharmacol Physiol; 2016 Mar; 43(3):343-54. PubMed ID: 26889660
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Study of association between interleukin-17 and interferon-gamma and recombinant human erythropoietin dose in patients undergoing peritoneal dialysis.
    de Oliveira WV; de Figueiredo RC; de Paula AS; Turani SD; Velloso MSS; Pinheiro MB; Gomes KB; Marinho MAS; Pinto SWL; Rios DRA
    Cytokine; 2017 Aug; 96():24-29. PubMed ID: 28282547
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Erythropoietin and the anemia of chronic diseases.
    De Marchi S; Pirisi M; Ferraccioli GF
    Clin Exp Rheumatol; 1993; 11(4):429-44. PubMed ID: 8403591
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Managing erythropoietin hyporesponsiveness.
    Kwack C; Balakrishnan VS
    Semin Dial; 2006; 19(2):146-51. PubMed ID: 16551293
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of iron in erythropoiesis in the absence and presence of erythropoietin therapy.
    Goodnough LT
    Nephrol Dial Transplant; 2002; 17 Suppl 5():14-8. PubMed ID: 12091601
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.